References
- Mössner E, Brünker P, Moser P et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new Type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 115(22), 4393–4402 (2010).
- García-Muñoz R, López-Díaz-de-Cerio A, Feliu J et al. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. Immunol. Res. 64(2), 548–557 (2016).
- Sehn LH, Goy A, Offner FC et al. Randomized Phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J. Clin. Oncol. 33, 3467–3474 (2015).
- Marcus R, Devies A, Ando K et al. Obinutuzumab for the first-line treatment of Follicular lymphoma. N. Eng. J. Med. 377(14), 1331–1344 (2017).
- Hiddemann W, Barbui AM, Canales MA et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the randomized Phase III GALLIUM study: influence of chemotherapy regimen on efficacy and safety. J. Clin. Oncol. 36, 2395–2404 (2018).
- Friedberg JW. Progress in advanced-stage follicular lymphoma. J. Clin. Oncol. 36, 2363–2365 (2018).
- Freeman CL, Morschhauser F, Sehn L et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 126(24), 2646–2649 (2015).
- García-Muñoz R, Aguinaga L, Feliu J et al. Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia. Immunotherapy 10(6), 491–499 (2018).
- Flinn IW, van der Jagt R, Khal BS et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123, 2944–2952 (2014).
- Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus Rituximab vs CHOP plus Rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomized, Phase III noninferiority trial. Lancet 381, 1203–1210 (2013).
- Shafer D, Smith MR, Borghaei H et al. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk. Res. 37(10), 1213–1215 (2013).
- García-Muñoz R, Izquierdo-Gil A, Muñoz A et al. Lymphocyte recovery is impaired in patients with chronic lymphocityc leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann. Hematol. 93, 1879–1887 (2014).
- Rituximab: an autologous effector lymphocytes in non-Hodgkin follicular lymphoma in response to first-line chemotherapy. ClinicalTrials.gov identifier NCT01329354.